Hologram Sciences at the World Economic Forum, or AI serving global health through precision nutrition

By Taking an AI-Powered Approach to Combat Malnutrition, Hologram Sciences Strengthens Precision Nutrition Platform At the 54th World Economic Forum, Hologram Sciences , an AI-driven health technology company, outlines its commitment to addressing historic healthcare challenges, particularly the malnutrition of patients. The company’s…

Read MoreHologram Sciences at the World Economic Forum, or AI serving global health through precision nutrition

Sensorion Receives Authorization to Initiate a Phase 1/2 Clinical Trial for SENS-501 (OTOF-GT), its Most Advanced Gene Therapy Candidate, in Select European Countries

a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces that it has received approval of its application to initiate a Phase 1/2 clinical trial (CTA) with SENS-501…

Read MoreSensorion Receives Authorization to Initiate a Phase 1/2 Clinical Trial for SENS-501 (OTOF-GT), its Most Advanced Gene Therapy Candidate, in Select European Countries

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Hackensack Meridian Health (“HMH”), a leading not-for-profit health care organization and the largest, most comprehensive and truly integrated network in New…

Read MoreCompass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

New OmniSYS XiFin Pharmacy Solutions CareALERTS™ Data Demonstrate Critical Role Pharmacists Play as Healthcare Providers

CareALERTS closes healthcare gaps including raising immunizations rates among seniors and adults On National Pharmacist Day, XiFin celebrates pharmacists and urges all U.S. states to recognize pharmacists as providers OmniSYS, the pharmacy division of XiFin, Inc., announced its 2023 end-of-year…

Read MoreNew OmniSYS XiFin Pharmacy Solutions CareALERTS™ Data Demonstrate Critical Role Pharmacists Play as Healthcare Providers

Global Portable Ultrasound Equipment Strategic Analysis Report 2023: Market to Reach $2.9 Billion by 2030 – A Bright Star of Evolutionary Journey of Ultrasound Technology – ResearchAndMarkets.com

The “Portable Ultrasound Equipment – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. Global Portable Ultrasound Equipment Market to Reach $2.9 Billion by 2030 The global market for Portable Ultrasound Equipment estimated at US$1.8 Billion in the year 2022, is projected…

Read MoreGlobal Portable Ultrasound Equipment Strategic Analysis Report 2023: Market to Reach $2.9 Billion by 2030 – A Bright Star of Evolutionary Journey of Ultrasound Technology – ResearchAndMarkets.com

Geneoscopy Files Inter Partes Review Petition Challenging Exact Sciences’ Patent

Extensive prior art renders Exact Sciences’ patent relating to stool collection and processing invalid Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that it has petitioned the United States…

Read MoreGeneoscopy Files Inter Partes Review Petition Challenging Exact Sciences’ Patent

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

KEYTRUDA is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients Approval marks third FDA-approved indication for KEYTRUDA in cervical cancer and 39th indication for KEYTRUDA in the US Merck (NYSE: MRK), known as MSD outside…

Read MoreFDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer